Biocon, Mylan's diabetic drug receives positive opinion from European Medicines Agency committee

Updated : December 14, 2020 12:28 PM IST

Biotechnology firm Biocon on Monday said its subsidiary Biocon Biologics and Mylan have received a positive opinion from the European Medicines Agency’s committee for medicinal products for human use (CHMP) recommending approval of the market authorisation of their product ’Kixelle’ use for the treatment of type 1 and 2 diabetes.

”Biocon Biologics and Mylan (a subsidiary of Viatris Inc.) have received a positive opinion from the European Medicines Agency’s committee for medicinal products for human use (CHMP) recommending approval of the market authorisation of Kixelle, a biosimilar Insulin Aspart, which is a rapid acting insulin for the treatment of type 1 and 2 diabetes,” Biocon said in a regulatory filing.

Also Read: Zydus Cadila gets tentative nod from USFDA to marketdiabetes drug

Biocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is expected early next year. Christiane Hamacher, CEO, Biocon Biologics, said the company will look forward to a final decision from the European Commission approving Insulin Aspart ”which will enable us to expand our offering to people with diabetes to include a rapid-acting insulin analog along with a long-acting insulin glargine”. Shares of Biocon were trading 0.58 percent lower at Rs 452.25 apiece on BSE.

Published : December 14, 2020 12:22 PM IST

Biocon, Mylan's diabetic drug receives positive opinion from European Medicines Agency committee

You May Also Like

Creators throng to Apple's new M1 Macs as they see gains in productivity

In Pics | COVID-19 data highlights for April 20: 2.59 lakh new cases, total death toll climbs to 1.80 lakh

ACC Q1 Earnings: Low operating costs unlikely to sustain, says Edelweiss Securities

Trending on CNBC-TV18

recommended for you